z-logo
open-access-imgOpen Access
CD11c Controls Herpes Simplex Virus 1 Responses To Limit Virus Replication during Primary Infection
Author(s) -
Sariah J. Allen,
Kevin R. Mott,
Aziz Alami Chentoufi,
Lbachir BenMohamed,
Steven L. Wechsler,
Christie M. Ballantyne,
Homayon Ghiasi
Publication year - 2011
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.05208-11
Subject(s) - biology , cd11c , herpes simplex virus , virology , acquired immune system , immunology , interferon , immune system , virus , cd8 , viral replication , immunity , innate immune system , phenotype , biochemistry , gene
CD11c is expressed on the surface of dendritic cells (DCs) and is one of the main markers for identification of DCs. DCs are the effectors of central innate immune responses, but they also affect acquired immune responses to infection. However, how DCs influence the efficacy of adaptive immunity is poorly understood. Here, we show that CD11c+ DCs negatively orchestrate both adaptive and innate immunity against herpes simplex virus type 1 (HSV-1) ocular infection. The effectiveness and quantity of virus-specific CD8+ T cell responses are increased in CD11c-deficient animals. In addition, the levels of CD83, CD11b, alpha interferon (IFN-α), and IFN-β, but not IFN-γ, were significantly increased in CD11c-deficient animals. Higher levels of IFN-α, IFN-β, and CD8+ T cells in the CD11c-deficient mice may have contributed to lower virus replication in the eye and trigeminal ganglia (TG) during the early period of infection than in wild-type mice. However, the absence of CD11c did not influence survival, severity of eye disease, or latency. Our studies provide for the first time evidence that CD11c expression may abrogate the ability to reduce primary virus replication in the eye and TG via higher activities of type 1 interferon and CD8+ T cell responses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here